Category Archives: BioUtah News
KT Tape Names Jessica Klodnicki As New CEO
AMERICAN FORK, Utah, June 22, 2022 /PRNewswire/ — KT Tape®, the leader in drug-free pain relief products, today announced that after a national executive search, the company’s board of directors has appointed Jessica Klodnicki as its new chief executive officer. Klodnicki is a recognized transformative leader in the outdoor brands and consumer products industry with […]
IONIQ Unveils LUNA3, Next-Generation Early-Stage Cancer Detection Platform
IONIQ Sciences unveiled its next-generation platform called LUNA3™ for early-stage cancer detection. LUNA3 is designed to accelerate the transition of cancer testing from the hospital and doctor’s office into pharmacies and ultimately into consumers’ homes.
ATL Technology Acquires Developer of Disposable Scopes and Micro-Endoscopic Solutions, BioVision Technologies, LLC
Springville, Utah June 21, 2022—ATL Technology (“ATL”), a joint development manufacturing partner to top medical device firms, announced the acquisition of BioVision Technologies, LLC (“BioVision”). ATL has a proven track record of developing custom interconnect solutions for energy driven medical devices. Using an engineer-to-engineer approach over the last two decades, the company has been expanding […]
Utah RDAC Joins Juneteenth Health Fair
Members of the Utah Rare Disease Advisory Council (RDAC) on Monday participated in the Utah Juneteenth Holiday Health & Wellness Expo, National Sickle Cell Day, held at the Gallivan Center, in Salt Lake City, Utah. Toya Jules and Matt Pearl, RDAC members and rare disease patients, exhibited at the day long event. “The RDAC felt it was important […]
Utah Life Sciences at BIO 2022
Utah’s life sciences industry left its mark on this week’s 2022 BIO International Convention at the San Diego Convention Center (June 13-16). Curavit, Curza, Recursion, Cytiva and Thermo Fisher showcased their companies at the convention that featured more than 3,000 companies and 100-plus panel sessions over four days. Topics included cell and gene therapies, next-gen […]
CenExel Acquires Apex Innovative Sciences
Premier CNS-Focused Research Facilities in California and New Jersey Join the CenExel Centers of Excellence Clinical Research Site Network
Sen. Romney Opposes Drug Importation as the Senate HELP Committee Advances User Fees
The Senate Health, Education, Labor and Pensions (HELP) Committee voted 13 to 9 on Tuesday to advance user fee reauthorization legislation.
Halia Therapeutics Announces First Participant Dosed in Phase 1 Clinical Study of HT-6184
HT-6184 is a novel NEK7/NLRP3 inhibitor
BD Collaborates with Mayo Clinic Platform, Leveraging Real-World Clinical Data to Improve Post-Market Device Surveillance, Drive Innovation for Patient Care
BD is among the first companies to enter innovative partnership with Mayo Clinic Platform for access to world’s largest collection of clinical data
University of Manchester Adds Carterra’s LSA® Instrument for High-Throughput Antibody Screening and Characterization
MANCHESTER, England & SALT LAKE CITY–(BUSINESS WIRE)–The University of Manchester, United Kingdom, and Carterra, Inc., the world leader in innovative technologies enabling high-throughput biology, announced today that the University of Manchester has added Carterra’s LSA instrument to its Biomolecular Analysis Core Facility (BACF) within the Faculty of Biology, Medicine and Health (FBMH). The BACF was […]
Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-3654, an Investigational Oral Inhibitor of PIM Kinases for the Treatment of Myelofibrosis
CAMBRIDGE, Mass., June 8, 2022 /PRNewswire/ — Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today announced the U.S. Food Drug and Administration (FDA) granted Orphan Drug Designation for TP-3654, the company’s proprietary investigational oral inhibitor of PIM kinases, for the treatment of myelofibrosis. “This designation is an important milestone in […]
ELEVAR THERAPEUTICS SHARES RESULTS OF PHASE 2 RIVOCERANIB TRIAL IN PATIENTS WITH PROGRESSIVE RECURRENT OR METASTATIC ADENOID CYSTIC CARCINOMA
CHICAGO, June 06, 2022 — Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today detailed the results of its Phase 2 clinical trial (Study RM-202) of rivoceranib, an orally administered tyrosine kinase inhibitor (TKI), in patients with progressive recurrent […]
